Form 4: CorMedix Director Robert Stewart Receives RSU Grant

CorMedix Inc. Director Robert Stewart was granted 30,453 restricted stock units, vesting in full on January 26, 2027.

Summary

• Robert Stewart, a Director of CorMedix Inc. (CRMD), received a grant of 30,453 restricted stock units (RSUs) on January 26, 2026.
• Each restricted stock unit represents the right to receive one share of CorMedix Inc. common stock.
• These restricted stock units will vest in full on January 26, 2027, subject to continued service on the vesting date.
• Following this transaction, Robert Stewart beneficially owns 66,453 shares of CorMedix Inc. common stock.
• A Power of Attorney was executed on January 14, 2026, appointing Beth Zelnick Kaufman as attorney-in-fact for Robert Stewart for SEC filings, including Forms 3, 4, 5, and 144.

Sentiment

Score: 6

Explanation: The grant of restricted stock units to a director is a standard compensation practice that aligns the director's interests with those of shareholders, which is generally viewed as a positive for corporate governance. However, it is a routine filing and does not indicate significant operational or financial news.

Positives

• Director Robert Stewart received a grant of 30,453 restricted stock units, which aligns his interests with those of shareholders by incentivizing long-term company performance.

Risks

• The vesting of the 30,453 restricted stock units is contingent upon Robert Stewart's continued service to CorMedix Inc. until January 26, 2027; failure to meet this condition would result in forfeiture.

Future Outlook

The restricted stock units granted to Robert Stewart are expected to vest in full on January 26, 2027, contingent upon his continued service to CorMedix Inc. until that date.

Management Comments

• Robert Stewart acknowledges that the attorney-in-fact, in serving in such capacity, is not assuming, nor is CorMedix Inc. assuming, any of his responsibilities to comply with Section 16 of the Securities Exchange Act of 1934, as amended.

Industry Context

This filing is a routine insider transaction report (Form 4) detailing equity compensation for a director. Such grants are a common practice across publicly traded companies, including those in the biotechnology and pharmaceutical sectors, to align the interests of management and directors with those of shareholders and to incentivize long-term commitment.

Comparison to Industry Standards

• The grant of restricted stock units (RSUs) as a form of equity compensation for directors is a standard practice widely adopted across various industries, including biotechnology and pharmaceuticals, to foster alignment with shareholder interests.
• The specified vesting schedule, which typically ranges from one to three years and is contingent on continued service, is consistent with common industry benchmarks for director equity awards.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant of restricted stock units to a director aligns management incentives with shareholder interests, potentially fostering long-term value creation and improved corporate governance.

Next Steps

• The restricted stock units are scheduled to vest in full on January 26, 2027, subject to Robert Stewart's continued service.

Key Dates

Keywords

CorMedix Inc., CRMD, Robert Stewart, Restricted Stock Units, RSU, Director, Insider Transaction, SEC Form 4, Equity Compensation, Corporate Governance